Annual report pursuant to Section 13 and 15(d)

Shareholders' Deficit

v3.22.4
Shareholders' Deficit
12 Months Ended
Dec. 31, 2022
Equity [Abstract]  
Shareholders' Deficit

8. Shareholders’ Deficit

The Company had 97.9 million, 100.8 million, and 120.1 million common shares outstanding as of December 31, 2022, 2021, and 2020, respectively. In December 2004, the Company authorized 7.5 million preference shares at $0.002 par value. The 7.5 million authorized preference shares remained unissued as of December 31, 2022. Preference shares may be issued from time to time in one or more series, each of such series to have such voting powers (full or limited or without voting powers), designations, preferences and relative, participating, optional or other special rights and qualifications, limitations or restrictions as determined by the Company’s board of directors.

Dividends

The Company has not declared or paid cash dividends since 2014. The declaration of future dividends is subject to the discretion of the Company’s board of directors and will depend upon various factors, including its earnings, financial condition, Herbalife Nutrition Ltd.’s available distributable reserves under Cayman Islands law, restrictions imposed by the 2018 Credit Facility and the terms of any other indebtedness that may be outstanding, cash requirements, future prospects and other factors deemed relevant by its board of directors.

Share Repurchases

On February 9, 2021, the Company’s board of directors authorized a new three-year $1.5 billion share repurchase program that will expire on February 9, 2024, which replaced the Company’s prior share repurchase authorization that was set to expire on October 30, 2023 and had approximately $7.9 million of remaining authorized capacity when it was replaced. This share repurchase program allows the Company, which includes an indirect wholly-owned subsidiary of Herbalife Nutrition Ltd., to repurchase the Company’s common shares at such times and prices as determined by management, as market conditions warrant, and to the extent Herbalife Nutrition Ltd.’s distributable reserves are available under Cayman Islands law. The 2018 Credit Facility permits the Company to repurchase its common shares as long as no default or event of default exists and other conditions, such as specified consolidated leverage ratios, are met. As of December 31, 2022, the remaining authorized capacity under the Company’s $1.5 billion share repurchase program was approximately $985.5 million.

During the year ended December 31, 2022, the Company repurchased approximately 3.7 million of its common shares through open-market purchases at an aggregate cost of approximately $131.8 million, or an average cost of $35.73 per share, and subsequently retired these shares. During January 2021, the Company repurchased from Mr. Carl C. Icahn and certain of his affiliates an aggregate of approximately 12.5 million common shares of the Company at an aggregate cost of approximately $600.0 million, or $48.05 per share, and subsequently retired these shares. In addition, during the year ended December 31, 2021, the Company repurchased approximately 7.9 million of its common shares through open-market purchases at an aggregate cost of approximately $382.7 million, or an average cost of $48.17 per share, and subsequently retired these shares. In total, during the year ended December 31, 2021, the Company repurchased approximately 20.4 million of its common shares at an aggregate cost of approximately $982.7 million, or an average cost of $48.10 per share. In August 2020, the Company completed its modified Dutch auction tender offer and then subsequently paid cash to repurchase and retire a total of approximately 15.4 million of its common shares at an aggregate cost of approximately $750.0 million, or $48.75 per share. In addition, during the year ended December 31, 2020, the Company repurchased approximately 3.0 million of its common shares through open-market purchases at an aggregate cost of approximately $142.1 million, or an average cost of $47.40 per share, and subsequently retired these shares. In total, during the year ended December 31, 2020, the Company repurchased approximately 18.4 million of its common shares at an aggregate cost of approximately $892.1 million, or an average cost of $48.53 per share.

As of December 31, 2021, the Company held approximately 10.0 million of treasury shares for U.S. GAAP purposes. These treasury shares increased the Company’s shareholders’ deficit and were reflected at cost within the Company’s accompanying consolidated balance sheet as of December 31, 2021. Although these shares were owned by an indirect wholly-owned subsidiary of the Company and remained legally outstanding, they were reflected as treasury shares under U.S. GAAP and therefore reduced the number of common shares outstanding within the Company’s consolidated financial statements and the weighted-average number of common shares outstanding used in calculating earnings per share. The common shares of Herbalife Nutrition Ltd. held by the indirect wholly-owned subsidiary, however, remained outstanding on the books and records of the Company’s transfer agent and therefore still carried voting and other share rights related to ownership of the Company’s common shares, which could be exercised. So long as it was consistent with applicable laws, such shares were voted by such subsidiary in the same manner, and to the maximum extent possible in the same proportion, as all other votes cast with respect to any matter properly submitted to a vote of Herbalife Nutrition Ltd.’s shareholders. In August 2022, the Company retired these 10.0 million treasury shares and as a result the amount of its treasury shares reflected at cost within the Company's accompanying consolidated balance sheet decreased by $328.9 million as of December 31, 2022, compared to December 31, 2021. The Company also allocated the excess of the original repurchase price of these common shares over the par value of the shares acquired between shareholders deficit and additional paid-in capital. As a result of the retirement of its treasury shares these approximately 10.0 million shares no longer remained legally outstanding.

The number of shares issued upon vesting or exercise for certain restricted stock units and SARs granted pursuant to the Company’s share-based compensation plans is net of the statutory withholding requirements that the Company pays on behalf of its employees. Although shares withheld are not issued, they are treated as common share repurchases in the Company’s consolidated financial statements, as they reduce the number of shares that would have been issued upon vesting. These shares do not count against the authorized capacity under the Company’s share repurchase program described above. During the years ended December 31, 2022, 2021, and 2020, the Company withheld shares on its vested restricted stock units and exercised SARs relating to its share-based compensation plans.

The Company reflects the aggregate purchase price of its common shares repurchased as an increase to shareholders’ deficit. The Company generally allocated the purchase price of the repurchased shares to accumulated deficit, common shares, and additional paid-in capital, with the exception of treasury shares, which are recorded separately on the Company’s consolidated balance sheets.

For the years ended December 31, 2022, 2021, and 2020, the Company’s share repurchases, inclusive of transaction costs, were $131.8 million, $982.7 million, and $893.9 million, respectively, under the Company’s share repurchase programs, and $14.9 million, $28.6 million, and $29.6 million, respectively, due to shares withheld for tax purposes related to the Company’s share-based compensation plans. For the years ended December 31, 2022, 2021, and 2020, the Company’s total share repurchases, including shares withheld for tax purposes, were $146.7 million, $1,011.3 million, and $923.5 million, respectively, and have been recorded as an increase to shareholders’ deficit within the Company’s consolidated balance sheets.

Accumulated Other Comprehensive Loss

The following table summarizes changes in accumulated other comprehensive loss by component during the years ended December 31, 2022, 2021, and 2020:

 

 

 

Changes in Accumulated Other Comprehensive Loss by Component

 

 

 

Foreign Currency
Translation
Adjustments

 

 

Unrealized (Loss) Gain on Derivatives

 

 

Total

 

 

 

(in millions)

 

Balance as of December 31, 2019

 

$

(211.6

)

 

$

(0.9

)

 

$

(212.5

)

Other comprehensive income before reclassifications, net of tax

 

 

33.2

 

 

 

1.7

 

 

 

34.9

 

Amounts reclassified from accumulated other comprehensive loss to income, net of tax(1)

 

 

 

 

 

(4.6

)

 

 

(4.6

)

Total other comprehensive income (loss), net of reclassifications

 

 

33.2

 

 

 

(2.9

)

 

 

30.3

 

Balance as of December 31, 2020

 

 

(178.4

)

 

 

(3.8

)

 

 

(182.2

)

Other comprehensive (loss) income before reclassifications, net of tax

 

 

(33.2

)

 

 

0.2

 

 

 

(33.0

)

Amounts reclassified from accumulated other comprehensive loss to income, net of tax(1)

 

 

 

 

 

3.4

 

 

 

3.4

 

Total other comprehensive (loss) income, net of reclassifications

 

 

(33.2

)

 

 

3.6

 

 

 

(29.6

)

Balance as of December 31, 2021

 

 

(211.6

)

 

 

(0.2

)

 

 

(211.8

)

Other comprehensive loss before reclassifications, net of tax

 

 

(36.6

)

 

 

(4.8

)

 

 

(41.4

)

Amounts reclassified from accumulated other comprehensive loss to income, net of tax(1)

 

 

 

 

 

3.0

 

 

 

3.0

 

Total other comprehensive loss, net of reclassifications

 

 

(36.6

)

 

 

(1.8

)

 

 

(38.4

)

Balance as of December 31, 2022

 

$

(248.2

)

 

$

(2.0

)

 

$

(250.2

)

 

(1) See Note 2, Basis of Presentation, and Note 11, Derivative Instruments and Hedging Activities, for information regarding the location within the consolidated statements of income of gains (losses) reclassified from accumulated other comprehensive loss to income during the years ended December 31, 2022, 2021, and 2020.

Other comprehensive income (loss) before reclassifications was net of tax expense of $1.1 million for foreign currency translation adjustments for the year ended December 31, 2022.

Other comprehensive income (loss) before reclassifications was net of tax expense of $0.2 million for foreign currency translation adjustments for the year ended December 31, 2021.

Other comprehensive income (loss) before reclassifications was net of tax benefit of $2.0 million and $0.6 million for foreign currency translation adjustments and unrealized gain (loss) on derivatives, respectively, for the year ended December 31, 2020. Amounts reclassified from accumulated other comprehensive loss to income was net of tax expense of $0.2 million for unrealized gain (loss) on derivatives for the year ended December 31, 2020.